secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001193125-24-266184
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharmaceuticals expands revolver to $885M, extends maturity to 2029
------------------------------------------------------------------------

- Revolving credit facility increased from $500M to $885M; maturity extended from May 2026 to Nov 2029.
- Initial applicable margin reduced by 125 bps: Term SOFR +2.00% and prime +1.00%.
- Facility was undrawn as of Nov 26, 2024; financial covenants apply only when drawn.
- Springing maturity provisions tied to 2026 exchangeable notes and 2028 term loan thresholds.
- Amendment adds new lenders and commits to customary conditions for effectiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524266184/0001193125-24-266184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524266184/d833314d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-266184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer